Skip to main content
SpringerLink
Log in

Bortezomib/dexamethasone/selinexor

Lack of efficacy

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Bentur OS, et al. Real-World Safety and Effectiveness of Selinexor-Based Regimens in Patients with Relapsed or Refractory Multiple Myeloma and Dialysis-Dependent Renal Impairment. Blood 140 (Suppl. 1): 12600-12602, Nov 2022. Available from: URL: https://dx.doi.org/10.1182/blood-2022-158060 [abstract]

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bortezomib/dexamethasone/selinexor. Reactions Weekly 1995, 43 (2024). https://doi.org/10.1007/s40278-024-53306-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-024-53306-y

Search

Navigation